丹麦，截至2025年3月4日的2024/25流感季节，增强流感疫苗对65岁及以上个体的影响。

IF 9.9 2区医学 Q1 INFECTIOUS DISEASES

Eurosurveillance Pub Date : 2025-03-01 DOI:10.2807/1560-7917.ES.2025.30.12.2500174

Hanne-Dorthe Emborg, Palle Valentiner-Branth, Ramona Trebbien, Amanda Bolt Botnen, Tyra Grove Krause, Bolette Søborg

{"title":"丹麦，截至2025年3月4日的2024/25流感季节，增强流感疫苗对65岁及以上个体的影响。","authors":"Hanne-Dorthe Emborg, Palle Valentiner-Branth, Ramona Trebbien, Amanda Bolt Botnen, Tyra Grove Krause, Bolette Søborg","doi":"10.2807/1560-7917.ES.2025.30.12.2500174","DOIUrl":null,"url":null,"abstract":"During the 2024/25 influenza season, enhanced and standard-dose influenza vaccines were available for individuals aged 65 and older. Compared with the standard-dose quadrivalent influenza vaccine (QIV), the adjuvanted QIV was significantly more effective, with an overall vaccine effectiveness (VE) of 48% (95% CI: 42-52) vs 33% (95% CI: 24-41) when considering both non-hospitalised and hospitalised patients. The high-dose QIV demonstrated similar effectiveness to the adjuvanted QIV. These findings support the inclusion of enhanced influenza vaccines in future vaccination programmes.","PeriodicalId":12161,"journal":{"name":"Eurosurveillance","volume":"30 12","pages":""},"PeriodicalIF":9.9000,"publicationDate":"2025-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11951413/pdf/","citationCount":"0","resultStr":"{\"title\":\"Enhanced influenza vaccines impact effectiveness in individuals aged 65 years and older, Denmark, 2024/25 influenza season up to 4 March 2025.\",\"authors\":\"Hanne-Dorthe Emborg, Palle Valentiner-Branth, Ramona Trebbien, Amanda Bolt Botnen, Tyra Grove Krause, Bolette Søborg\",\"doi\":\"10.2807/1560-7917.ES.2025.30.12.2500174\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"During the 2024/25 influenza season, enhanced and standard-dose influenza vaccines were available for individuals aged 65 and older. Compared with the standard-dose quadrivalent influenza vaccine (QIV), the adjuvanted QIV was significantly more effective, with an overall vaccine effectiveness (VE) of 48% (95% CI: 42-52) vs 33% (95% CI: 24-41) when considering both non-hospitalised and hospitalised patients. The high-dose QIV demonstrated similar effectiveness to the adjuvanted QIV. These findings support the inclusion of enhanced influenza vaccines in future vaccination programmes.\",\"PeriodicalId\":12161,\"journal\":{\"name\":\"Eurosurveillance\",\"volume\":\"30 12\",\"pages\":\"\"},\"PeriodicalIF\":9.9000,\"publicationDate\":\"2025-03-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11951413/pdf/\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Eurosurveillance\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.2807/1560-7917.ES.2025.30.12.2500174\",\"RegionNum\":2,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q1\",\"JCRName\":\"INFECTIOUS DISEASES\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Eurosurveillance","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.2807/1560-7917.ES.2025.30.12.2500174","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"INFECTIOUS DISEASES","Score":null,"Total":0}

引用次数: 0

摘要

在2014 /25年流感季节，为65岁及以上的个人提供了增强剂量和标准剂量的流感疫苗。与标准剂量的四价流感疫苗（QIV）相比，佐剂QIV明显更有效，在考虑非住院和住院患者时，总体疫苗有效性（VE）为48%(95% CI: 42-52) vs 33%（95% CI: 24-41）。高剂量QIV显示出与佐剂QIV相似的效果。这些发现支持在未来的疫苗接种规划中纳入增强型流感疫苗。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

查看原文本刊更多论文

Enhanced influenza vaccines impact effectiveness in individuals aged 65 years and older, Denmark, 2024/25 influenza season up to 4 March 2025.

During the 2024/25 influenza season, enhanced and standard-dose influenza vaccines were available for individuals aged 65 and older. Compared with the standard-dose quadrivalent influenza vaccine (QIV), the adjuvanted QIV was significantly more effective, with an overall vaccine effectiveness (VE) of 48% (95% CI: 42-52) vs 33% (95% CI: 24-41) when considering both non-hospitalised and hospitalised patients. The high-dose QIV demonstrated similar effectiveness to the adjuvanted QIV. These findings support the inclusion of enhanced influenza vaccines in future vaccination programmes.

求助全文

通过发布文献求助，成功后即可免费获取论文全文。去求助

来源期刊

Eurosurveillance INFECTIOUS DISEASES-

CiteScore

32.70

自引率

2.10%

发文量

430

审稿时长

3-8 weeks

期刊介绍： Eurosurveillance is a European peer-reviewed journal focusing on the epidemiology, surveillance, prevention, and control of communicable diseases relevant to Europe.It is a weekly online journal, with 50 issues per year published on Thursdays. The journal includes short rapid communications, in-depth research articles, surveillance reports, reviews, and perspective papers. It excels in timely publication of authoritative papers on ongoing outbreaks or other public health events. Under special circumstances when current events need to be urgently communicated to readers for rapid public health action, e-alerts can be released outside of the regular publishing schedule. Additionally, topical compilations and special issues may be provided in PDF format.